Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation
- PMID: 38458222
- DOI: 10.1016/S0140-6736(24)00052-7
Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation
Abstract
Inflammatory bowel disease (IBD) affects reproductive planning due to psychological effects and mechanical problems related to surgery. Children of people with IBD have an increased risk of about 10% if one parent has IBD and up to 33% if both parents have IBD. The fertility of people with IBD is similar to the general population, but fertility might be reduced in individuals with active IBD, ileal pouch-anal anastomosis, or perianal Crohn's disease. Flaring disease during pregnancy increases complications, such as preterm birth. Thus, disease management with appropriate medications can optimise outcomes. As most medications have minimal fetal risks, people with IBD should be informed about the risks of stopping medications and the importance of maintaining remission. A period of disease remission is advisable before pregnancy and could reduce the risks for both the pregnant person and the fetus. Flexible endoscopy, intestinal ultrasound, and gadolinium-free magnetic resonance enterography are safe during pregnancy. We provide state-of-the-art knowledge on the basis of the latest evidence to ensure successful pregnancy outcomes in controlled IBD.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests SES holds stocks in Merk and Johnson & Johnson and is a consultant for Janssen, Takeda, Bristol Myers Squibb, Gilead, Prometheus, and Surrozen. All other authors declare no competing interests.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
